期刊
BEST PRACTICE & RESEARCH CLINICAL HAEMATOLOGY
卷 29, 期 4, 页码 324-328出版社
ELSEVIER SCI LTD
DOI: 10.1016/j.beha.2016.10.003
关键词
Acute myeloid leukemia; AML; Phase 3; Primary refractory AML; Relapsed AML
类别
Fewer patients with primary refractory AML (PREF) are entered into phase 3 trials than are patients with relapsed AML This is particularly noteworthy because data from phase 3 trials for newly diagnosed AML indicated PREF and relapse are equally common. Here I discuss three possible reasons for this discrepancy. First, there is disagreement whether the criterion for PREF AML should be failure of one or two courses of initial induction therapy. Second, there may be an impression that PREF AML is qualitatively worse than relapsed AML. Third, there may be a general unwillingness to randomize patients with such poor prognoses. (C) 2016 Elsevier Ltd. All rights reserved.
作者
我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。
推荐
暂无数据